Platelet Glycoprotein IIb/IIIa Inhibitors in Cardiovascular Disease by A Michael LincoffPlatelet Glycoprotein IIb/IIIa Inhibitors in Cardiovascular Disease by A Michael Lincoff

Platelet Glycoprotein IIb/IIIa Inhibitors in Cardiovascular Disease

EditorA Michael Lincoff

Paperback | November 9, 2010

Pricing and Purchase Info

$332.22 online 
$375.95 list price save 11%
Earn 1661 plum® points

In stock online

Ships free on orders over $25

Not available in stores

about

This substantially revised second edition contains new chapters on the role of GPIIb/IIIa blockade during acute coronary syndromes or with fibrinolytic therapy during acute myocardial infarctions, and updated and expanded information on the latest trials of GP IIb/IIIa inhibition during percutaneous coronary intervention. Additional improvements include a new chapter on outcomes with chronic oral GP IIb/IIIa blockade following acute coronary syndromes, discussion of GPIIb/IIIa blockade with other platelet and thrombin inhibitors, and a review of the potential effects beyond inhibition of platelet aggregation. Platelet Glycoprotein IIb/IIIa inhibitors in Cardiovascular Disease, Second Edition offers today's physicians, cardiologists, emergency room doctors, and basic scientists the most complete and authoritative review of the state-of-the-art in glycoprotein Iib/IIIa receptor inhibitor use.
Title:Platelet Glycoprotein IIb/IIIa Inhibitors in Cardiovascular DiseaseFormat:PaperbackDimensions:486 pages, 10 × 7.01 × 0.03 inPublished:November 9, 2010Publisher:Humana PressLanguage:English

The following ISBNs are associated with this title:

ISBN - 10:1617374083

ISBN - 13:9781617374081

Look for similar items by category:

Customer Reviews of Platelet Glycoprotein IIb/IIIa Inhibitors in Cardiovascular Disease

Reviews

Table of Contents

Part I. Basic PrinciplesThrombosis in Acute Coronary Syndromes and Coronary InterventionsThaddeus R. Tolleson and Robert A. HarringtonPlatelet AdhesionEdward F. PlowGlycoprotein IIb/IIIa in Platelet Aggregation and Acute Arterial ThrombosisPatrick Andre and David R. PhillipsGlycoprotein IIb/IIIa Antagonists: Development of Abciximab and Pharmacology of AbciximabTirofiban, and Eptifibatide, Barry S. CollerPart II. Glycoprotein IIb/IIIa Blockade During Coronary InterventionAbciximab During Percutaneous Coronary Intervention: EPIC, EPILOG, and EPISTENT TrialsA. Michael LincoffEptifibatide in Coronary Intervention: The IMPACT and ESPRIT TrialsJean-Pierre Dery, J. Conor O'Shea, and James E. TchengTirofiban in Interventional Cardiology: The RESTORE and TARGET TrialsNicholas Valettas and Howard C. HerrmannOverview of the Glycoprotein IIb/IIIa Interventional TrialsA. Michael Lincoff and Eric J. TopolPart III. Glycoprotein IIb/IIIa Blockade for Acute Ischemic SyndromesThe Use of Abciximab in Therapy-Resistant Unstable Angina: Clinical and Angiographic Results of the CAPTURE Pilot Trial and the CAPTURE StudyMarcel J. B. M. van den Brand and Maarten L. SimoonsUnstable Angina Trials: PARAGON, PURSUIT, PRISM, PRISM-PLUS, and GUSTO-IVDavid J. MoliternoPlatelet Glycoprotein IIb/IIIa Inhibitors and an Invasive StrategyChristopher P. CannonGlycoprotein IIb/IIIa Receptor Blockade in Myocardial Infarction: Adjunctive Therapy to Percutaneous Coronary InterventionsFranz-Josef NeumannGlycoprotein IIb/IIIa Receptor Blockade in Acute Myocardial Infarction: Adjunctive Therapy to FibrinolysisSorin J. BrenerPart IV. Practical Issues and Future ApplicationsEconomics of Glycoprotein IIb/IIIa InhibitionDaniel B. MarkPlatelet Monitoring and Interaction of Glycoprotein IIb/IIIa Antagonists with Other Antiplatelet AgentsSteven R. SteinhublPlatelet Glycoprotein IIb/IIIa Antagonists: Their Interaction with Low-Molecular-Weight Heparins and Direct Thrombin InhibitorsAmol S. Bapat, Naji Yazbek, and Neal S. KleimanOral AgentsL. Kristin NewbyPlatelet Glycoprotein IIb/IIIa Inhibitors: Effects Beyond the PlateletDean J. Kereiakes and Pascal J. Goldschmidt-ClermontCerebrovascular InterventionsLeslie Cho and Jay S. YadavCerebrovascular Aspects of Glycoprotein IIb/IIIa Receptor InhibitorsCathy A. SilaEvolution of Drug Development in Evidence-Based Medicine: Summary and the FutureDavid E. Kandzari, David F. Kong, and Robert M. CaliffIndex

Editorial Reviews

"...provides the reader with extensive and profound information about this new class, based on data from completed and ongoing trials...can be recommended not only to cardiologists but to all clinicians and researchers interested in this field." -Intensive Care Medicine